All In Biotech

NDA 216023 · Blue Earth

Posluma

Flotufolastat F-18 Gallium · Intravenous · Radioactive Diagnostic Agent

Novel

CDER novel approval, May 25, 2023: To use with positron emission tomography imaging in certain patients with prostate cancer

Last checked: Nov 20, 2026Latest source record: Jan 10, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

May 25, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

4

0 Phase 3, 3 recruiting

FAERS reports

49

6 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 25, 2026.

POSLUMA is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy. with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. POSLUMA is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. ( 1 )

Mechanism: Flotufolastat F 18 binds to PSMA (IC50 = 4.4 nM) expressed on cells, including prostate cancer cells, and is internalized. Prostate cancer cells usually overexpress PSMA. Fluorine-18 is a ß+ emitting radionuclide that can be detected using positron emission tomography.

Therapeutic areas: Oncology · Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 25, 2023 Original approval · Type 1 - New Molecular Entity NovelLetterLabelReview
1 products under this application
  • POSLUMA · FLOTUFOLASTAT F-18 GALLIUM 25ML (8-158mCi/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Flotufolastat F-18 Gallium" as an intervention, any sponsor and status, largest first.

All 4 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • positron emission tomogram abnormal14
  • no adverse event9
  • drug effect less than expected8
  • hot flush4
  • incorrect dose administered4
  • overdose4
  • wrong product administered3
  • covid-192
  • dizziness2
  • drug ineffective2
  • product dispensing error2
  • underdose2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202413
202521
202615

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Blue Earth

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.